(MedPage Today) — SAN FRANCISCO — Post-surgical adjuvant nivolumab (Opdivo) improved survival outcomes in muscle-invasive bladder cancer (MIBC), regardless of the use of neoadjuvant chemotherapy, according to updated analyses of the CheckMate…
Source link : https://www.medpagetoday.com/meetingcoverage/mgucs/114247
Author :
Publish date : 2025-02-17 18:00:00
Copyright for syndicated content belongs to the linked Source.
